Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

Ítems similars

• Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial
  per: Hochberg, Marc C., et al.
  Publicat: (2019)
• Brief Report: Intraarticular Sprifermin Not Only Increases Cartilage Thickness, but Also Reduces Cartilage Loss: Location‐Independent Post Hoc Analysis Using Magnetic Resonance Imaging
  per: Eckstein, Felix, et al.
  Publicat: (2015)
• Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
  per: Eckstein, Felix, et al.
  Publicat: (2021)
• Subregional Laminar Cartilage MR Spin-Spin Relaxation Times (T2) in Osteoarthritic Knees with and without Medial Femorotibial Cartilage Loss – Data from the Osteoarthritis Initiative (OAI)
  per: Wirth, W., et al.
  Publicat: (2017)
• Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial
  per: Roemer, Frank W., et al.
  Publicat: (2016)